BioProcess International is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Rahul Singhvi is the Chief Operating Officer of Takeda’s Global Vaccine Business Unit and is responsible for global supply of vaccines at the Takeda Pharmaceutical Company.
Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. a Nasdaq-listed biotechnology company (NVAX). During his tenure at Novavax, Dr. Singhvi transformed the company from a specialty pharmaceutical business to a premier vaccine company and increased its valuation from $30M to over $300M. Dr. Singhvi’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.
Dr. Singhvi is a member of the Board of Directors of Immunocellular Therapeutics (NYSE: IMUC), a member of the Executive Advisory Board at the Leonard Davis Institute (LDI) of Health Economics at the University of Pennsylvania, and a mentor instructor in the Undergraduate Projects Opportunity Program (UPOP) at MIT.
Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his MS and ScD chemical engineering degrees from MIT. He received an MBA degree from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.